Katherine Peters, MD, PhD FAAN

Department of Neurology Duke University School of Medicine Durham, NC Associate Professor of Neurosurgery Director of Supportive Care

Dr. Peters (Associate Professor of Neurosurgery, Department of Neurology, Duke University School of Medicine, NC) is board certified by the American Board of Psychiatry and Neurology, and the United Council of Neurologic Subspecialties for neuro-oncology. She received both her PhD and MD from Stanford, and completed her Internship and Residency Fellowships (Cognitive Neuroscience) at Johns Hopkins University and Duke (Neuro-Oncology). She then joined the Preston Robert Tisch Brain Tumor Center at Duke University School of Medicine (Director of Supportive Care) where she actively sees and cares for patients with primary brain tumors. She is engaged in clinical trials for the treatment of brain tumors, with a focus on the improvement of quality of life and cognition. Dr. Peters’ awards and honors include Women Leading in Neurology Fellow, Team Science Award AACR and Eun-Kyu Lee Award for Excellence in Teaching of Clinical Neurology, Neurology Department, Duke University.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org